Natarajan Ravendhran
Distinguished in Macroamylasemia

Dr. Natarajan Ravendhran

Hepatology | Gastroenterology
Johns Hopkins Medicine
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Lutherville, MD 

Distinguished in Macroamylasemia
Johns Hopkins Medicine
Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Lutherville, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Natarajan Ravendhran is a hepatologist specializing in the diagnosis, treatment and management of liver diseases. He received his medical degree from Stanley Medical College, University of Madras in India, completed his residency in internal medicine at what is now Ascension Saint Agnes Hospital in Maryland and a residency in surgery at Railway Hospital in Madras, India. Dr. Ravendhran performed fellowship training in hepatology under the mentorship of Eugene and Leon Schiff at the University of Miami. Additionally, he received fellowship training in gastroenterology and liver disease at the University of Missouri. Dr. Ravendhran received a master’s degree in business administration in medical services management from The Johns Hopkins University. He is a fellow of the American Association for the Study of Liver Diseases and the American Gastroenterological Association, and is a member of the European Association for the Study of the Liver. Dr. Ravendhran is interested in exploring cholestatic disorders. He has participated in many clinical trials that focus on hepatitis B and C, in addition to metabolic dysfunction-associated steatotic liver disease trials. He enjoys teaching, rounding with fellows and seeing patients, and his motto is “Patients come first!”.

Dr. Ravendhran is rated as a Distinguished provider by MediFind in the treatment of Macroamylasemia. His top areas of expertise are Non-Alcoholic Fatty Liver Disease, Hepatitis, Visceromegaly, Enlarged Liver, and Endoscopy.

His clinical research consists of co-authoring 22 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Johns Hopkins Carey Business School, MBA, MBA, 2001
Residency
Ascension Maryland Saint Agnes Hospital, Internal Medicine, 1979
Specialties
Hepatology
Gastroenterology
Licenses
Internal Medicine in MD
Board Certifications
American Board Of Internal Medicine
Fellowships
University of Missouri Hospital and Clinics, Gastroenterology and Hepatology, 1982
University of Miami Jackson Health, Medicine-Hepatology, 1980
Hospital Affiliations
The Johns Hopkins Hospital
Johns Hopkins Bayview Medical Center
Languages Spoken
English
Tamil
Telugu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Johns Hopkins Health Care & Surgery Center - Green Spring Station, Lutherville
Joppa Concourse STE 205, Lutherville, MD 21093
Call: 410-933-7495

Additional Areas of Focus

Dr. Ravendhran has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


7 Clinical Trials

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy
Enrollment Status: Completed
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)
Enrollment Status: Terminated
Publish Date: November 25, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 6 Less Clinical Trials

22 Total Publications

Association of Carbohydrate Antigen 19-9 Elevation Among Patients With Alcohol-Related Liver Disease Undergoing Liver Transplant.
Association of Carbohydrate Antigen 19-9 Elevation Among Patients With Alcohol-Related Liver Disease Undergoing Liver Transplant.
Journal: Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
Published: July 08, 2025
View All 22 Publications
Similar Doctors
Agazi G. Gebreselassie
Advanced in Macroamylasemia
Dr. Agazi G. Gebreselassie
Gastroenterology | Hospital Medicine
Advanced in Macroamylasemia
Dr. Agazi G. Gebreselassie
Gastroenterology | Hospital Medicine

Woodholme Gastroenterology Assoc PA

1838 Greene Tree Road, Suite 400, Suite 400, 
Baltimore, MD 
 (9.0 miles away)
410-602-7782
Languages Spoken:
English, Amharic, Tigrinya
See accepted insurances

Agazi Gebreselassie is a Gastroenterologist and a Hospital Medicine provider in Baltimore, Maryland. Dr. Gebreselassie is rated as an Advanced provider by MediFind in the treatment of Macroamylasemia. His top areas of expertise are Jaundice, Macroamylasemia, Portal Hypertension, Endoscopy, and Colonoscopy.

Advanced in Macroamylasemia
Dr. Nadim G. Haddad
Gastroenterology
Advanced in Macroamylasemia
Dr. Nadim G. Haddad
Gastroenterology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (37.2 miles away)
703-558-1400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nadim Haddad is a Gastroenterologist in Washington, Washington, D.c.. Dr. Haddad is rated as a Distinguished provider by MediFind in the treatment of Macroamylasemia. His top areas of expertise are Gallstones, Gallbladder Disease, Bile Duct Obstruction, Gallbladder Removal, and Endoscopy. Dr. Haddad is currently accepting new patients.

Advanced in Macroamylasemia
Dr. Andrew Axelrad
Gastroenterology
Advanced in Macroamylasemia
Dr. Andrew Axelrad
Gastroenterology

Gastroenterology Associates Of Northern Virginia, LLC

3022 Williams Dr, Suite 301, 
Fairfax, VA 
 (45.4 miles away)
703-698-8960
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrew Axelrad is a Gastroenterologist in Fairfax, Virginia. Dr. Axelrad is rated as an Advanced provider by MediFind in the treatment of Macroamylasemia. His top areas of expertise are Ulcerative Colitis, Familial Adenomatous Polyposis, Macroamylasemia, Gastrectomy, and Endoscopy.

VIEW MORE MACROAMYLASEMIA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ravendhran's expertise for a condition
ConditionClose
    • Distinguished
    • Cirrhosis
      Dr. Ravendhran is
      Distinguished
      . Learn about Cirrhosis.
      See more Cirrhosis experts
    • Enlarged Liver
      Dr. Ravendhran is
      Distinguished
      . Learn about Enlarged Liver.
      See more Enlarged Liver experts
    • Hepatitis
      Dr. Ravendhran is
      Distinguished
      . Learn about Hepatitis.
      See more Hepatitis experts
    • Hepatitis B
      Dr. Ravendhran is
      Distinguished
      . Learn about Hepatitis B.
      See more Hepatitis B experts
    • Hepatitis C
      Dr. Ravendhran is
      Distinguished
      . Learn about Hepatitis C.
      See more Hepatitis C experts
    • Macroamylasemia
      Dr. Ravendhran is
      Distinguished
      . Learn about Macroamylasemia.
      See more Macroamylasemia experts
    View All 11 Distinguished Conditions
    • Advanced
    • Alcoholic Cirrhosis
      Dr. Ravendhran is
      Advanced
      . Learn about Alcoholic Cirrhosis.
      See more Alcoholic Cirrhosis experts
    • Esophageal Varices
      Dr. Ravendhran is
      Advanced
      . Learn about Esophageal Varices.
      See more Esophageal Varices experts
    • Jaundice
      Dr. Ravendhran is
      Advanced
      . Learn about Jaundice.
      See more Jaundice experts
    • Nonalcoholic Steatohepatitis (NASH)
      Dr. Ravendhran is
      Advanced
      . Learn about Nonalcoholic Steatohepatitis (NASH).
      See more Nonalcoholic Steatohepatitis (NASH) experts
    • Experienced
    • Ascites
      Dr. Ravendhran is
      Experienced
      . Learn about Ascites.
      See more Ascites experts
    • Autoimmune Hepatitis
      Dr. Ravendhran is
      Experienced
      . Learn about Autoimmune Hepatitis.
      See more Autoimmune Hepatitis experts
    • Banti's Syndrome
      Dr. Ravendhran is
      Experienced
      . Learn about Banti's Syndrome.
      See more Banti's Syndrome experts
    • Caroli Disease
      Dr. Ravendhran is
      Experienced
      . Learn about Caroli Disease.
      See more Caroli Disease experts
    • Cholangitis
      Dr. Ravendhran is
      Experienced
      . Learn about Cholangitis.
      See more Cholangitis experts
    • Endoscopy
      Dr. Ravendhran is
      Experienced
      . Learn about Endoscopy.
      See more Endoscopy experts
    View All 16 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.